Prostatic Hypertrophy Agt-Type I, II 5Alpha Reductase Inhib

Dual type I and type II 5-alpha reductase inhibitors comprise a therapeutic subclass of antiandrogenic agents formulated to manage symptomatic benign prostatic hyperplasia In clinical practice, this dual-isoenzyme inhibition is primarily represented by dutasteride, which is utilized to relieve obstructive urinary symptoms and lower the long-term risk of acute urinary retention and prostate-related surgery

Dual type I and type II 5-alpha reductase inhibitors comprise a therapeutic subclass of antiandrogenic agents formulated to manage symptomatic benign prostatic hyperplasia In clinical practice, this dual-isoenzyme inhibition is primarily represented by dutasteride, which is utilized to relieve obstructive urinary symptoms and lower the long-term risk of acute urinary retention and prostate-related surgery

These agents work by competitively blocking both the type 1 and type 2 isoenzymes of 5-alpha reductase, thereby suppressing the peripheral and intraprostatic conversion of testosterone to dihydrotestosterone

This profound androgen suppression halts cellular proliferation and induces epithelial atrophy within the gland, leading to reduced prostate volume and improved lower urinary tract urinary flow In clinical practice, this dual-isoenzyme inhibition is primarily represented by dutasteride, which is utilized to relieve obstructive urinary symptoms and lower the long-term risk of acute urinary retention and prostate-related surgery

This profound androgen suppression halts cellular proliferation and induces epithelial atrophy within the gland, leading to reduced prostate volume and improved lower urinary tract urinary flow